Robust aversive effects of trace amine-associated receptor 1 activation in mice

Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediato...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropsychopharmacology (New York, N.Y.) N.Y.), 2023-09, Vol.48 (10), p.1446-1454
Hauptverfasser: Shabani, Shkelzen, Houlton, Sydney, Ghimire, Bikalpa, Tonello, Derek, Reed, Cheryl, Baba, Harue, Aldrich, Sara, Phillips, Tamara J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1454
container_issue 10
container_start_page 1446
container_title Neuropsychopharmacology (New York, N.Y.)
container_volume 48
creator Shabani, Shkelzen
Houlton, Sydney
Ghimire, Bikalpa
Tonello, Derek
Reed, Cheryl
Baba, Harue
Aldrich, Sara
Phillips, Tamara J
description Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediator of aversive methamphetamine effects. Methamphetamine is a TAAR1 agonist, but also has actions at monoamine transporters. Whether exclusive activation of TAAR1 has aversive effects was not known at the time we conducted our studies. Mice were tested for aversive effects of the selective TAAR1 agonist, RO5256390, using taste and place conditioning procedures. Hypothermic and locomotor effects were also examined, based on prior evidence of TAAR1 mediation. Male and female mice of several genetic models were used, including lines selectively bred for high and low methamphetamine drinking, a knock-in line in which a mutant form of Taar1 that codes for a non-functional TAAR1 was replaced by the reference Taar1 allele that codes for functional TAAR1, and their matched control line. RO5256390 had robust aversive, hypothermic and locomotor suppressing effects that were found only in mice with functional TAAR1. Knock-in of the reference Taar1 allele rescued these phenotypes in a genetic model that normally lacks TAAR1 function. Our study provides important data on TAAR1 function in aversive, locomotor, and thermoregulatory effects that are important to consider when developing TAAR1 agonists as therapeutic drugs. Because other drugs can have similar consequences, potential additive effects should be carefully considered as these treatment agents are being developed.
doi_str_mv 10.1038/s41386-023-01578-4
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10425385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2850417320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-3c3cfc0011e4569aa244928f8e7492167b8a11d23800a4125e08ec33b28962f13</originalsourceid><addsrcrecordid>eNpdkUFLHTEQx0NpqU_tF-hBAr14SZvJZHezp1JEa0EQRMFbyMubrZG3m2eSfeC3b-yzoj3NYX7z5z_8GPsM8itINN-yBjStkAqFhKYzQr9jC-i0FC3q2_dsIU2PAhBv99h-zvfyiWrNR7aHnWwabcyCXV7F5ZwLd1tKOWyJ0zCQL5nHgZfkPHE3homEyzn64AqteCJPmxITB-58CVtXQpx4mPgYPB2yD4NbZ_r0PA_Yzdnp9cm5uLj8-evkx4XwGqEI9OgHXwsB6abtnVNa98oMhro6oe2WxgGsFBopnQbVkDTkEZfK9K0aAA_Y913uZl6OtPI01bZru0lhdOnRRhfs280U7uzvuLUgtWrQNDXh-DkhxYeZcrFjyJ7WazdRnLNVRkJvQKq2ol_-Q-_jnKb6X6UaqaFDJSuldpRPMedEw0sbkPZJmN0Js1WY_SvM6np09PqPl5N_hvAP4AqQcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2850417320</pqid></control><display><type>article</type><title>Robust aversive effects of trace amine-associated receptor 1 activation in mice</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Shabani, Shkelzen ; Houlton, Sydney ; Ghimire, Bikalpa ; Tonello, Derek ; Reed, Cheryl ; Baba, Harue ; Aldrich, Sara ; Phillips, Tamara J</creator><creatorcontrib>Shabani, Shkelzen ; Houlton, Sydney ; Ghimire, Bikalpa ; Tonello, Derek ; Reed, Cheryl ; Baba, Harue ; Aldrich, Sara ; Phillips, Tamara J</creatorcontrib><description>Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediator of aversive methamphetamine effects. Methamphetamine is a TAAR1 agonist, but also has actions at monoamine transporters. Whether exclusive activation of TAAR1 has aversive effects was not known at the time we conducted our studies. Mice were tested for aversive effects of the selective TAAR1 agonist, RO5256390, using taste and place conditioning procedures. Hypothermic and locomotor effects were also examined, based on prior evidence of TAAR1 mediation. Male and female mice of several genetic models were used, including lines selectively bred for high and low methamphetamine drinking, a knock-in line in which a mutant form of Taar1 that codes for a non-functional TAAR1 was replaced by the reference Taar1 allele that codes for functional TAAR1, and their matched control line. RO5256390 had robust aversive, hypothermic and locomotor suppressing effects that were found only in mice with functional TAAR1. Knock-in of the reference Taar1 allele rescued these phenotypes in a genetic model that normally lacks TAAR1 function. Our study provides important data on TAAR1 function in aversive, locomotor, and thermoregulatory effects that are important to consider when developing TAAR1 agonists as therapeutic drugs. Because other drugs can have similar consequences, potential additive effects should be carefully considered as these treatment agents are being developed.</description><identifier>ISSN: 0893-133X</identifier><identifier>ISSN: 1740-634X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/s41386-023-01578-4</identifier><identifier>PMID: 37055488</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Agonists ; Alleles ; Animal models ; Animals ; Drug abuse ; Female ; Male ; Mental disorders ; Methamphetamine ; Mice ; Monoamine transporter ; Phenotypes ; Receptors, G-Protein-Coupled - agonists ; Receptors, G-Protein-Coupled - genetics</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2023-09, Vol.48 (10), p.1446-1454</ispartof><rights>2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</rights><rights>This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023.</rights><rights>This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-3c3cfc0011e4569aa244928f8e7492167b8a11d23800a4125e08ec33b28962f13</citedby><cites>FETCH-LOGICAL-c431t-3c3cfc0011e4569aa244928f8e7492167b8a11d23800a4125e08ec33b28962f13</cites><orcidid>0000-0002-7350-6323</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425385/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425385/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37055488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shabani, Shkelzen</creatorcontrib><creatorcontrib>Houlton, Sydney</creatorcontrib><creatorcontrib>Ghimire, Bikalpa</creatorcontrib><creatorcontrib>Tonello, Derek</creatorcontrib><creatorcontrib>Reed, Cheryl</creatorcontrib><creatorcontrib>Baba, Harue</creatorcontrib><creatorcontrib>Aldrich, Sara</creatorcontrib><creatorcontrib>Phillips, Tamara J</creatorcontrib><title>Robust aversive effects of trace amine-associated receptor 1 activation in mice</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediator of aversive methamphetamine effects. Methamphetamine is a TAAR1 agonist, but also has actions at monoamine transporters. Whether exclusive activation of TAAR1 has aversive effects was not known at the time we conducted our studies. Mice were tested for aversive effects of the selective TAAR1 agonist, RO5256390, using taste and place conditioning procedures. Hypothermic and locomotor effects were also examined, based on prior evidence of TAAR1 mediation. Male and female mice of several genetic models were used, including lines selectively bred for high and low methamphetamine drinking, a knock-in line in which a mutant form of Taar1 that codes for a non-functional TAAR1 was replaced by the reference Taar1 allele that codes for functional TAAR1, and their matched control line. RO5256390 had robust aversive, hypothermic and locomotor suppressing effects that were found only in mice with functional TAAR1. Knock-in of the reference Taar1 allele rescued these phenotypes in a genetic model that normally lacks TAAR1 function. Our study provides important data on TAAR1 function in aversive, locomotor, and thermoregulatory effects that are important to consider when developing TAAR1 agonists as therapeutic drugs. Because other drugs can have similar consequences, potential additive effects should be carefully considered as these treatment agents are being developed.</description><subject>Agonists</subject><subject>Alleles</subject><subject>Animal models</subject><subject>Animals</subject><subject>Drug abuse</subject><subject>Female</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Methamphetamine</subject><subject>Mice</subject><subject>Monoamine transporter</subject><subject>Phenotypes</subject><subject>Receptors, G-Protein-Coupled - agonists</subject><subject>Receptors, G-Protein-Coupled - genetics</subject><issn>0893-133X</issn><issn>1740-634X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkUFLHTEQx0NpqU_tF-hBAr14SZvJZHezp1JEa0EQRMFbyMubrZG3m2eSfeC3b-yzoj3NYX7z5z_8GPsM8itINN-yBjStkAqFhKYzQr9jC-i0FC3q2_dsIU2PAhBv99h-zvfyiWrNR7aHnWwabcyCXV7F5ZwLd1tKOWyJ0zCQL5nHgZfkPHE3homEyzn64AqteCJPmxITB-58CVtXQpx4mPgYPB2yD4NbZ_r0PA_Yzdnp9cm5uLj8-evkx4XwGqEI9OgHXwsB6abtnVNa98oMhro6oe2WxgGsFBopnQbVkDTkEZfK9K0aAA_Y913uZl6OtPI01bZru0lhdOnRRhfs280U7uzvuLUgtWrQNDXh-DkhxYeZcrFjyJ7WazdRnLNVRkJvQKq2ol_-Q-_jnKb6X6UaqaFDJSuldpRPMedEw0sbkPZJmN0Js1WY_SvM6np09PqPl5N_hvAP4AqQcA</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Shabani, Shkelzen</creator><creator>Houlton, Sydney</creator><creator>Ghimire, Bikalpa</creator><creator>Tonello, Derek</creator><creator>Reed, Cheryl</creator><creator>Baba, Harue</creator><creator>Aldrich, Sara</creator><creator>Phillips, Tamara J</creator><general>Nature Publishing Group</general><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7350-6323</orcidid></search><sort><creationdate>20230901</creationdate><title>Robust aversive effects of trace amine-associated receptor 1 activation in mice</title><author>Shabani, Shkelzen ; Houlton, Sydney ; Ghimire, Bikalpa ; Tonello, Derek ; Reed, Cheryl ; Baba, Harue ; Aldrich, Sara ; Phillips, Tamara J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-3c3cfc0011e4569aa244928f8e7492167b8a11d23800a4125e08ec33b28962f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Agonists</topic><topic>Alleles</topic><topic>Animal models</topic><topic>Animals</topic><topic>Drug abuse</topic><topic>Female</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Methamphetamine</topic><topic>Mice</topic><topic>Monoamine transporter</topic><topic>Phenotypes</topic><topic>Receptors, G-Protein-Coupled - agonists</topic><topic>Receptors, G-Protein-Coupled - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shabani, Shkelzen</creatorcontrib><creatorcontrib>Houlton, Sydney</creatorcontrib><creatorcontrib>Ghimire, Bikalpa</creatorcontrib><creatorcontrib>Tonello, Derek</creatorcontrib><creatorcontrib>Reed, Cheryl</creatorcontrib><creatorcontrib>Baba, Harue</creatorcontrib><creatorcontrib>Aldrich, Sara</creatorcontrib><creatorcontrib>Phillips, Tamara J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shabani, Shkelzen</au><au>Houlton, Sydney</au><au>Ghimire, Bikalpa</au><au>Tonello, Derek</au><au>Reed, Cheryl</au><au>Baba, Harue</au><au>Aldrich, Sara</au><au>Phillips, Tamara J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Robust aversive effects of trace amine-associated receptor 1 activation in mice</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>48</volume><issue>10</issue><spage>1446</spage><epage>1454</epage><pages>1446-1454</pages><issn>0893-133X</issn><issn>1740-634X</issn><eissn>1740-634X</eissn><abstract>Drugs that stimulate the trace amine-associated receptor 1 (TAAR1) are under clinical investigation as treatments for several neuropsychiatric disorders. Previous studies in a genetic mouse model of voluntary methamphetamine intake identified TAAR1, expressed by the Taar1 gene, as a critical mediator of aversive methamphetamine effects. Methamphetamine is a TAAR1 agonist, but also has actions at monoamine transporters. Whether exclusive activation of TAAR1 has aversive effects was not known at the time we conducted our studies. Mice were tested for aversive effects of the selective TAAR1 agonist, RO5256390, using taste and place conditioning procedures. Hypothermic and locomotor effects were also examined, based on prior evidence of TAAR1 mediation. Male and female mice of several genetic models were used, including lines selectively bred for high and low methamphetamine drinking, a knock-in line in which a mutant form of Taar1 that codes for a non-functional TAAR1 was replaced by the reference Taar1 allele that codes for functional TAAR1, and their matched control line. RO5256390 had robust aversive, hypothermic and locomotor suppressing effects that were found only in mice with functional TAAR1. Knock-in of the reference Taar1 allele rescued these phenotypes in a genetic model that normally lacks TAAR1 function. Our study provides important data on TAAR1 function in aversive, locomotor, and thermoregulatory effects that are important to consider when developing TAAR1 agonists as therapeutic drugs. Because other drugs can have similar consequences, potential additive effects should be carefully considered as these treatment agents are being developed.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>37055488</pmid><doi>10.1038/s41386-023-01578-4</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7350-6323</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-133X
ispartof Neuropsychopharmacology (New York, N.Y.), 2023-09, Vol.48 (10), p.1446-1454
issn 0893-133X
1740-634X
1740-634X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10425385
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Agonists
Alleles
Animal models
Animals
Drug abuse
Female
Male
Mental disorders
Methamphetamine
Mice
Monoamine transporter
Phenotypes
Receptors, G-Protein-Coupled - agonists
Receptors, G-Protein-Coupled - genetics
title Robust aversive effects of trace amine-associated receptor 1 activation in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A01%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Robust%20aversive%20effects%20of%20trace%20amine-associated%20receptor%201%20activation%20in%20mice&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Shabani,%20Shkelzen&rft.date=2023-09-01&rft.volume=48&rft.issue=10&rft.spage=1446&rft.epage=1454&rft.pages=1446-1454&rft.issn=0893-133X&rft.eissn=1740-634X&rft_id=info:doi/10.1038/s41386-023-01578-4&rft_dat=%3Cproquest_pubme%3E2850417320%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2850417320&rft_id=info:pmid/37055488&rfr_iscdi=true